Feasibility, Tolerability, Safety and Efficacy of a Pantothenic Acid Based Dietary Supplement in Subjects with Mild to Moderate Facial Acne Blemishes

Jillian L. Capodice*

Nutraceutical Medical Research, New York City, USA.
Email: jcapodice@nutraceuticalmedicalresearch.com

Received May 5th, 2012; revised June 8th, 2012; accepted June 20th, 2012

ABSTRACT

Objective: It has been suggested that pantothenic acid may have antibacterial and skin softening activity. The aim of this study was to explore the feasibility, tolerability, safety and preliminary efficacy of oral administration of a dietary supplement containing pantothenic acid in healthy human males and females with mild to moderate facial acne vulgaris.

Methods: An open-label, single arm study of healthy adults who had been previously diagnosed with mild to moderate acne vulgaris was performed. Subjects were asked to take the study agent, a dietary supplement containing pantothenic acid, for eight weeks. The primary endpoint of the study was to assess the feasibility of oral administration of the study agent in subjects over an eight week period. Safety and tolerability were measured utilizing the assessment of adverse events by the National Cancer Institute’s Common Criteria for Adverse Event Reporting. Secondary endpoints measuring the efficacy of an oral pantothenic acid dietary supplement for the treatment of mild to moderate facial acne utilized changes in the extent of global facial skin blemishes, assessment of quality of life utilizing the Dermatology Life Quality Index (DLQI) and analysis of questions about the subject’s beliefs and attitudes towards skin care and lifestyle.

Results: Eleven subjects were enrolled and ten completed the study (90.9%). There were no reported adverse events. Of the 10 evaluable subjects, the average age (mean ± SD) was 31.8 ± 8. Analysis of the global number of skin blemishes demonstrated a significant mean reduction in lesion count following the use of the study agent at week 8 (endpoint) (11.18 ± 6.38, p = 0.02) compared to the average number of baseline blemishes (20.45 ± 10.44). DLQI scores were significantly lower at week 8 vs. baseline (p = 0.0194).

Conclusions: The results from this study indicated that the administration of a pantothenic based dietary supplement in healthy human adults with mild to moderate acne vulgaris is feasible, safe and well tolerated. Secondary analysis shows that administration of the study agent significantly reduced global facial blemishes. Further randomized, placebo-controlled trials are warranted.

Keywords: Pantothenic Acid; Dietary Supplement; Facial Blemishes; Acne

1. Introduction

Acne is a common disease of the hair follicles in the skin associated with an oil gland. Acne often appears in teens but can persist in up to two-thirds of adults [1,2]. Studies have shown that people with acne may suffer significant psychosocial burden and report poor quality of life [2]. The mainstays of treatment include over-the-counter and prescription pharmaceutical drugs including oral and topical antibiotics and retinoids and oral contraceptives [3]. Other procedures include lasers, phototherapy and other light sources [3]. Recently, approaches from complementary and alternative medicine (CAM) including the use of natural products including topical agents containing vitamin or botanical ingredients, dietary interventions and acupuncture have been examined [3,4]. Some agents may have clear mechanisms of action such as vitamins and dietary supplements like pyridoxine or omega-3 fatty acids however there is limited data on the use of dietary supplements in the treatment of dermatologic conditions such as acne [4]. A recent study found that subjects with acne were more apt to use CAM based on lower risk, perceived safety of natural agents, holistic attitudes towards health and improved quality of life, however prospective analysis of various practices and procedures are lacking and need to be performed in order to determine feasibility, tolerability and efficacy of these approaches [4,5]. Given this background we chose to examine the feasibility, tolerability, and safety of a novel dietary supplement containing pantothenic acid in adult males and females with mild to moderate skin blemishes. Secon-
dary aims were to measure changes in the extent of glo-
bal facial skin lesions and quality of life.

2. Materials and Methods

2.1. Subjects

Healthy human male and female volunteers over the age
of 18, with a previously diagnosed history of acne vul-
garis, more than 10 facial blemishes of any type, able to
understand and sign the informed consent in the English
language and in good health were eligible for the study.
Excluded from the study were subjects taking any oral or
topical prescription drug for acne vulgaris, subjects cur-
rently undergoing treatment for acne vulgaris besides
daily hygienic skin care, known renal or hepatic impair-
ment, scheduled elective surgery or other procedures
requiring general anaesthesia during the study, participa-
tion in another research study involving an investiga-
tional product in the past month, hypersensitivity or
known allergy to any ingredients in the study agent, cur-
rent use of any dietary supplement for skin health (be-
sides a multivitamin), history or presence of gastric ulcer
or duodenal ulcer, history of any gynaecologic condition,
history of any psychiatric disorder and current smoking
or smoking within the past month. The protocol for this
study was conducted under Good Clinical Practice in
concordance with the Declaration of Helsinki and it’s a-
mendments.

2.2. Study Procedures

The study was performed between December 2011 and
April 2012. Consecutive human volunteers that met the
eligibility criteria were instructed to read, understand and
sign the written informed consent and model release dis-
claimer. At baseline, subjects were asked to complete
demographic information, have a photograph taken of
their face, complete the Dermatology Life Quality Index
(DLQI), and other health history information. The DLQI
is a general questionnaire that evaluates quality of life
(QOL) in dermatology patients and consists of ten ques-
tions about symptoms, feelings, daily activities, type of
clothing, social or physical activities, exercise, job or
education, interpersonal relationships, marriage relation-
ships, and treatment. Higher scores indicate a poorer
quality of life [6]. Subjects were then assigned to take the
study agent, the dietary supplement, Pantothen (Panto-
then™, Avilan Marketing LLC, New York, NY), two
tablets twice a day with food, for eight weeks. Each 4
tablet dose of Pantothen contain the following ingredi-
ents: thiamine—1.5 mg, riboflavin—1.7 mg, niacin—20
mg, pyridoxine—2 mg, folic acid—400 mcg, cyanocob-
alamin—6 mcg, biotin—300 mcg, pantothenic acid—
2.2 g and L-carnitine—733.3 mg. At weeks 4 (mid-point)
and week 8 (end-point) volunteers were asked about their
compliance in taking the study agent and any side effects
and tolerability as measured by the National Cancer In-
titute’s Common Toxicity Criteria for Adverse Events
3.0 (NCI CTCAE). Subjects were also asked to complete
the DLQI and have a photograph of their face taken. At
the final visit overall satisfaction with the study agent
was assessed using a 5-point scale: 2 = marked im-
provement, 1 = slight improvement, 0 = unchanged, −1 =
worsening, −2 = marked worsening.

2.3. Statistics

The primary feasibility outcome was number of subjects
enrolled versus those completing the study defined as
80% of the volunteers completing the 4-week visit and/or
70% of volunteers completing all 8 weeks of consuming
the study agent. The tolerability and safety outcome was
the incidence of adverse effects, complication/illness and/
or serious medical events due to the study agent as
measured by the NCI CTCAE. The secondary efficacy
outcome of this study was change in the number of
global facial blemishes from baseline to week 8 as mea-
ured by lesion count. Other outcomes were scores on the
DLQI. The number of facial blemishes and DLQI scores
were measured by a paired t-test comparing counts/
scores at baseline (week 0) to week 8. Descriptive analy-
zes were performed for demographics utilizing charac-
teristic measures such as mean, standard deviation, and
range.

3. Results

3.1. Subjects and Feasibility

In total 13 subjects were screened, 11 subjects were en-
rolled and 10 completed the study. The 8-week comple-
tion rate (90.0%) met the feasibility endpoint. Of the 10
evaluable subjects the mean ± SD age was 31.8 ± 8.4.
Demographics and baseline characteristics are summa-
rized in Table 1. The reasons for premature withdrawal
were lost to follow up [1].

3.2. Safety and Tolerability Outcomes

No serious side effects were reported throughout the stu-
dy and there were no reported adverse events.

3.3. Facial Blemishes

The area of the face that was most affected in the study
population was the cheek, followed by the forehead and
chin (60 vs. 20 vs. 20 percent respectively). Analysis of
the number of facial skin blemishes (global acne count)
demonstrated a significant mean reduction in lesion
count from baseline (lesion count 20.45 ± 10.44) to week
Table 1. Demographics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>10</td>
</tr>
<tr>
<td>Mean age, years ± SD</td>
<td>31.8 ± 8.4</td>
</tr>
<tr>
<td>Sex, no (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2 (20%)</td>
</tr>
<tr>
<td>Female</td>
<td>8 (80%)</td>
</tr>
<tr>
<td>Race, no (%)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>5 (50%)</td>
</tr>
<tr>
<td>Black</td>
<td>2 (20%)</td>
</tr>
<tr>
<td>Latino</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>Asian</td>
<td>1 (10%)</td>
</tr>
<tr>
<td>BMI (mean, SD)</td>
<td>24.3 ± 3.8</td>
</tr>
<tr>
<td>Baseline global facial lesion</td>
<td>20.45 ± 10.44</td>
</tr>
<tr>
<td>Area most predominately affected</td>
<td></td>
</tr>
<tr>
<td>Cheek</td>
<td>6 (60%)</td>
</tr>
<tr>
<td>Forehead</td>
<td>2 (20%)</td>
</tr>
<tr>
<td>Chin</td>
<td>2 (20%)</td>
</tr>
</tbody>
</table>

8 lesion count (11.18 ± 6.38, p = 0.02) (Figure 1(a)). Figure 1(b) shows a subject at baseline versus week 8 reduction in global acne count in a study participant.

3.4. Dermatology Life Quality Index and Patient Reported Outcomes

The mean ± SD DLQI score at baseline vs. week 8 was 9.73 ± 4.2 vs. 6.09 ± 2.21, p = 0.0194. 6 of 10 (60%) of volunteers reported marked improvement, 3 of 10 (30%) reported slight improvement and only 1 of 10 (10%) reported no change in overall subject satisfaction.

4. Discussion

Pantothenic acid (vitamin B5) is a water-soluble B-complex vitamin that has may have beneficial effects on skin health. The results of this study demonstrated it was both feasible and safe for healthy human volunteers with known mild to moderate acne to take a dietary supplement (PantothenTM) containing pantothenic acid. Our results also showed that there was a greater than 56% reduction in the number of global facial blemishes after 8 weeks of Pantothen supplementation. Significantly lower scores on the Dermatology Life Quality Index corresponding to improved quality of life were also found in subjects taking the study agent.

It has been suggested that pantothenic acid and some of its analogs may have antibacterial and skin softening activity. Pantothenic acid is converted into 4’-phosphopantetheine which is then converted to co-enzyme A (CoA) utilizing adenosine tri-phosphate (ATP) [7-9]. CoA is involved in lipid metabolism and many other cellular processes and it has been shown that pantothenic acid may regulate epidermal barrier function through proliferation and differentiation of keratinocytes via CoA metabolism [10]. It is possible that the reduction in the amount of global skin lesions in volunteers following oral administration of the pantothenic acid based study agent may function through these mechanisms. However the exact mechanism of this effect is not understood.

The bioavailability of pantothenic acid has been reported in the range of 40 - 63 percent and amounts found in 24-hour urine samples have been shown to correlate with intake [11]. However in the adult with acne, little is known about the role of co-enzyme A and other factors which may cause acne including relationships to sebum production, keratination alteration and/or effect on inflammatory modulators [12]. While it is uncommon for adults to suffer from clinically significant pantothenic acid deficiency, it has been postulated that low levels and/or dysregulation of fatty acid metabolism due to
pantothenic acid deficiency may be a factor in acne pathogenesis [13]. Even though pantothenic acid is the main ingredient in Pantothen, there are a number of other vitamins that may contribute to a synergistic mechanism of action. This could include the B-complex vitamins and/or L-carnitine which has been recently shown to reduce sebum secretion in a human sebaceous cell line [14].

This study also demonstrated improved quality of life in subjects with facial blemishes as measured by the Dermatology Life Quality Index. It has been well demonstrated that adults with acne have reported reduced quality of life with regard to dissatisfaction and patient bother [2]. Moreover, it has been suggested that all studies of acne include assessments of quality of life because such assessments appear to be important correlates in measuring the success of treatment [15].

The limitations of this study are that we tested feasibility in subjects with heterogeneous lesions, had a small sample size and no control group. Due to these factors our exploratory findings cannot be directly attributed to the administration of the study agent as it is possible that volunteers improved because they made lifestyle or other changes that were not reported in their follow up visits.

Strengths of our study include pilot analysis of feasibility and safety that will enable us to better design and power a larger study and examine potential mechanisms of action of the study agent and dosage. Given the feasibility, tolerability, safety and positive trend in improving symptoms and quality of life, a larger randomized, placebo controlled study of Pantothen is warranted.

REFERENCES


